ArticleVaccines2024
Optimizing Varicella Vaccination Strategy: A Study on Age and Dose Impacts on Antibody Levels.
Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Global burden of varicella in children aged 5-9 y, relationship with vaccination policy indicators, and projected trends to 2030.Human vaccines & immunotherapeutics · 2026Article
- Impact of two-dose varicella vaccination in Guangzhou: An interrupted time-series study.Human vaccines & immunotherapeutics · 2026Article
- Evaluation of a thermostable Newcastle disease virus D58 strain by in ovo vaccination and challenge study.Virus genes · 2026Article
- Prevention of varicella-zoster virus infection in early childhood children: effect of 1 versus 2 doses of varicella vaccine on antibody levels.Infection · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Seropositivity study of Varicella in Healthy Populations in Guangzhou, China. Infection with varicella-zoster virus (VZV) leads to skin and mucous membranes blisters and the complications can be life threatening. A seroepidemiological study conducted from 2020 to 2022 in Guangzhou, China, aimed to evaluate varicella antibody levels. We measured varicella antibody concentrations using an enzyme-linked immunosorbent assay. A total of 3300 people were enrolled in the study. The mean varicella antibody level was 171.2 mIU/mL (95% CI: 158.9, 184.4), with an overall positivity rate of 67.00% (95% CI: 65.37, 68.60). The mean level of those positive subjective was 581.2 mIU/mL (95% CI: 552.3, 611.5). Varicella antibody levels were found to be influenced by age, vaccination dosage, and history of varicella infection. Antibody level increased with age and the number of vaccinations. The antibody induced by the varicella vaccine remained at protective levels for at least 6 years post-vaccination. We recommend two doses of the varicella vaccine for both children and adults and the integration of the varicella vaccine into the national routine immunization program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.